Moderna Inc. (MRNA)
Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views
Stocks of major vaccine makers dropped on Monday after the Food and Drug Administration's (FDA) top vaccine official Dr. Peter Marks resigned, citing conflicts with Health and Human Services (HHS) Secretary Robert F. Kennedy (RFK) Jr. over his views on immunization.
Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard
Biotech investors are grappling with fresh uncertainty following the abrupt resignation of Dr. Peter Marks, a key figure in the US Food and Drug Administration.
Why Moderna Stock Is Plummeting Today
Shares of Moderna (MRNA -9.35%) are falling on Monday. The company's stock lost 7.9% as of 1:30 p.m.
Moderna, Inc. (MRNA) Is a Trending Stock: Facts to Know Before Betting on It
Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
4 Things You Need to Know if You Buy Moderna Stock Today
It's been nearly five years since Moderna (MRNA -1.60%) emerged as a biotech industry disruptor, with its COVID-19 vaccine playing a landmark role in tackling the global pandemic in late 2020. Despite its generating record sales and profits through 2022, early projections of sustained demand for coronavirus vaccinations failed to materialize, leading to a sharp drop in the business.
Moderna Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell?
Given the uncertainty around its top-line growth, short-term investors should exercise caution when investing in MRNA stock.
Moderna (MRNA) Advances But Underperforms Market: Key Facts
In the latest trading session, Moderna (MRNA) closed at $34.71, marking a +0.26% move from the previous day.
Down 93%, Is It Finally Time to Buy Moderna?
As we near the five-year anniversary of the COVID-19 pandemic, it's a good time to revisit the drugmaker stock that was top of mind back then. A few years ago, Moderna (MRNA 0.93%) stock soared on the back of the highly successful vaccine it developed in record time.
Moderna (MRNA) Presents at Barclays 27th Annual Global Healthcare Conference (Transcript)
Moderna (NASDAQ:MRNA ) Barclays 27th Annual Global Healthcare Conference March 11, 2025 1:30 PM ET Company Participants Rose Loughlin - EVP of Research Lavina Talukdar - SVP, Head of IR Conference Call Participants Gena Wang - Barclays Gena Wang Good afternoon, everyone. My name is Gena Wang.
Why Moderna Stock Has Surged 20% This Week Despite Mixed News
Moderna stock has surged more than 20% this week after regulatory filings showed several executives bought shares on the open market. The post Why Moderna Stock Has Surged 20% This Week Despite Mixed News appeared first on Investor's Business Daily.
Moderna: Insider Buy Signal
Insider buying signals a market shift for Moderna, Inc. after years of relentless sales, with CEO Stephane Bancel purchasing MRNA shares due to perceived undervaluation. Moderna cut revenue guidance for 2025 to $1.5 to $2.5 billion, though the biotech has a strong pipeline of 10 drugs targeting a $30 billion market. Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities.
Here's Why Moderna Stock Soared 16% on Wednesday
The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.
